The US government has a further option for the supply of another 500 million doses in the longer term. Sanofi is leading the clinical development and registration of the COVID-19 vaccine and ...
with twice-weekly dosing by intravenous infusion after a titration period of two once-weekly doses, based on the patient's body weight. Sanofi estimates that the annual cost for a typical patient ...
Four years after Sanofi shelled out $125 million for global rights to Biond Biologic | The company is handing back the tumor ...
The approval is for both a 3 milliliter single-patient-use prefilled pen and a 10 milliliter multiple-dose vial ... FDA granted approval of Merilog to Sanofi (SNY)-Aventis U.S. Published first ...
Teva and Sanofi's duvakitug showed promising results in a Phase 2b study for ulcerative colitis and Crohn's disease, with plans for a Phase 3 trial in 2025.
Clinical Trials Arena on MSN18d
Sanofi and Teva report new outcomes from Phase IIb trial of duvakitugSanofi and Teva Pharmaceuticals have reported new outcomes from the randomised Phase IIb RELIEVE UCCD trial of human immunoglobulin G 1(IgG1)-λ2 monoclonal antibody, duvakitug, in treating moderate-to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback